<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04208399</url>
  </required_header>
  <id_info>
    <org_study_id>CR108713</org_study_id>
    <secondary_id>2019-003071-20</secondary_id>
    <secondary_id>56136379HPB1009</secondary_id>
    <nct_id>NCT04208399</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of Hepatic Impairment on JNJ-56136379</brief_title>
  <official_title>A Single-Dose, Open-Label, Parallel-Group Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of JNJ-56136379</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Sciences Ireland UC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Sciences Ireland UC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the pharmacokinetics (PK) of a single oral dose of&#xD;
      JNJ-56136379 in participants with liver cirrhosis and impaired hepatic function when compared&#xD;
      with healthy participants with normal hepatic function and no liver cirrhosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 9, 2020</start_date>
  <completion_date type="Actual">March 26, 2021</completion_date>
  <primary_completion_date type="Actual">March 26, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Concentration of JNJ-56136379</measure>
    <time_frame>Up to Day 21</time_frame>
    <description>Plasma concentration of oral dose of JNJ-56136379 will be assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Part A: Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with liver cirrhosis with moderate hepatic impairment will receive a single oral dose of JNJ-56136379 in fed condition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with normal liver function with no liver cirrhosis will receive a single oral dose of JNJ-56136379 in fed condition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Group 3 (optional)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with liver cirrhosis with mild hepatic impairment will receive a single oral dose of JNJ-56136379 in fed condition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Group 4 (optional)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with liver cirrhosis with severe hepatic impairment will receive a single oral dose of JNJ-56136379 in fed condition.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-56136379</intervention_name>
    <description>JNJ-56136379 will be administered orally in fed condition.</description>
    <arm_group_label>Part A: Group 1</arm_group_label>
    <arm_group_label>Part A: Group 2</arm_group_label>
    <arm_group_label>Part B: Group 3 (optional)</arm_group_label>
    <arm_group_label>Part B: Group 4 (optional)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  For all participants: Body mass index (BMI) between 18.0 and 38 kilogram per meter&#xD;
             square (kg/m2), extremes included; Woman of childbearing potential must not be&#xD;
             pregnant; Highly effective contraceptive measures in place for female participants of&#xD;
             childbearing potential or male participants with female partners of childbearing&#xD;
             potential; Non-smoker or light smoker as defined per protocol.&#xD;
&#xD;
          -  For Healthy Participants with Normal Hepatic Function and No Liver Cirrhosis:&#xD;
             Demographically comparable to the study groups with hepatic impairment with respect to&#xD;
             sex, age (+/-10 years), and body weight (+/-10 kilogram [kg]); Participants must be in&#xD;
             good health clinically and biologically as defined per protocol.&#xD;
&#xD;
          -  For Participants with Liver Cirrhosis and Moderate or Mild or Severe Hepatic&#xD;
             Impairment: Must have a total Child-Pugh score of 5 or 6, inclusive (mild); or 7 to 9,&#xD;
             inclusive (moderate); or 10 to 15, inclusive (severe) as determined by the&#xD;
             investigator; Must have liver cirrhosis with fibro scan readout greater than (&gt;) 12.5&#xD;
             Kilopascal (kPa) as cut-off at screening&#xD;
&#xD;
          -  Participants with controlled hypertension, with problems directly associated with the&#xD;
             primary diagnosis of hepatic impairment and with concurrent stable medical conditions&#xD;
             if the condition(s) will not introduce an additional risk factor and will not&#xD;
             interfere with the study objectives.&#xD;
&#xD;
          -  Concomitant medications to treat underlying disease states or medical conditions&#xD;
             related to hepatic impairment are allowed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of / or current clinically significant medical illness that could interfere&#xD;
             with the interpretation of the study results.&#xD;
&#xD;
          -  Known allergies, hypersensitivity, or intolerance to JNJ-6379 or its excipients.&#xD;
&#xD;
          -  History of drug or alcohol abuse within 1 year before screening or positive test&#xD;
             results at screening and Day -1.&#xD;
&#xD;
          -  Blood or blood products donated or substantial loss of blood (more than 500&#xD;
             milliliters [mL]) within 3 months before the study starts&#xD;
&#xD;
          -  Experimental drug received (including investigational vaccines) or experimental&#xD;
             medical device used within 1 month or within a period less than 10 times the drug's&#xD;
             half-life, whichever is longer, before the first dose of the study intervention is&#xD;
             scheduled.&#xD;
&#xD;
          -  Evidence of infection with human immunodeficiency virus (HIV)-1 and HIV-2, hepatitis&#xD;
             A, B or C (except if sustained virologic response to hepatitis C virus [HCV]&#xD;
             treatment).&#xD;
&#xD;
          -  Inability to fast for 10 hours.&#xD;
&#xD;
          -  Signs of hepatocellular carcinoma or history of biliary obstruction within the past 2&#xD;
             years.&#xD;
&#xD;
          -  Lack of good or reasonable venous access.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Sciences Ireland UC Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Sciences Ireland UC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>APEX GmbH</name>
      <address>
        <city>Munchen</city>
        <zip>81241</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR108713</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 20, 2019</study_first_submitted>
  <study_first_submitted_qc>December 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2019</study_first_posted>
  <last_update_submitted>April 19, 2021</last_update_submitted>
  <last_update_submitted_qc>April 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

